Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children
Information source: Ferrer Internacional S.A.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Dermatomycoses
Intervention: ciclopirox (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: Ferrer Internacional S.A. Official(s) and/or principal investigator(s):
Jose C Moreno, Prof, PhD, Principal Investigator, Affiliation: Hospital Reina Sofia, Cordoba, Spain
Summary
Ciclopirox olamine (CiclochemŪ) is a pyridone broad spectrum antifungal drug which has
shown activity on dermatophytes, yeasts, moulds, actinomycetes and some bacteria. Its
mechanism of action is based on a fungicidal activity by inhibiting the cellular captation
of essential substances needed for the metabolism and growth of the fungi. On the other
hand, this drug binds irreversibly with cell structures as mitochondria, ribosomes,
microsomes and cell wall. After dermal application, Ciclopirox olamine undergoes skin
penetration, being only absorbed a 1,5% of the applied dose. Clinical efficacy has been
studied in patients above 10 years with superficial dermatomycoses (dermatophytoses,
candidiasis and pityriasis versicolor) and the percentage of clinical healing ranged from
77% to 91% after 2-4 weeks of twice a day topical application. In all the studies, the
safety profile has been very good, showing only a very low rate of adverse events of mild to
moderate intensity. There are very few previous available data on the application of this
compound in children under 10 years of age. A single study had been performed with a
solution formulation in patients from 6 to 29 months with diaper candidiasis, showing good
efficacy and tolerability in these patients. The present study aims to show the safety and
tolerability of ciclopirox olamine in a cream formulation in patients from 3 months to 10
years with dermatomycoses.
Clinical Details
Official title: Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Primary outcome: To evaluate skin lesion condition as a measure of safety and tolerability of ciclopirox olamine treated dermatomycoses patients from 3 months to 10 years.
Secondary outcome: Explore clinical efficacy of topically applied ciclopirox olamine cream in patients with dermatomycoses.Explore mycological efficacy of topically applied ciclopirox olamine cream in patients with dermatomycoses Explore relapse rate
Detailed description:
A multicenter, open, prospective, Phase IV study of Ciclopirox olamine on patients from 3
months to 10 years with all kinds of dermatomycoses. All body areas were treatable except
scalp and nails (no tinea on the scalp nor onychomycoses) . Cream applied BID between 6. 00
and 10. 00am and 7. 00 and 10. 00pm daily for 4 weeks. Control visit after 4 more weeks without
treatment was performed in order to evaluate the relapse rate.
Eligibility
Minimum age: 3 Months.
Maximum age: 10 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients from 3 months to 10 years of age.
- Patients diagnosed of dermatomycoses produced by yeasts or dermatophytes by KOH
technique at the inclusion moment, which has to be confirmed by culture.
- Obtention of the informed consent of the parents or legal representatives of the
patients
Exclusion Criteria:
- Previous treatment with oral or topical antifungal drugs.
- Hypersensitivity to ciclopirox olamine or some of the cream excipients.
- Use of topical or oral steroids concomitantly.
- Patients with mycoses on the scalp or nails.
Locations and Contacts
Additional Information
Starting date: October 2008
Last updated: July 19, 2012
|
